维普期刊资源整合服务平台（V6.5）

160篇 您的检索式：作者名="Berek JS"

选中清除导出查看参考文献查看引证文献引用追踪共8页首页上一页第1页下一页末页 /8 跳转

	题名	作者	年代	出处	被引量
1	Lower urinary tract resection as part of cytoreductive surgery for ovarian cancer显示文摘	Berek JS Hacker NF Lagasse LD	1982	Gynecol Oncol1982，13，：	1
2	Lymph node-positive stage Ⅲ C ovarian cancer: a separate entity显示文摘	Berek JS	2009	Int J Gynecol Cancer2009，19，2：	1
3	Monoclonal antibody of ovarian cancer显示文摘	Nieodemus CF Berek JS	2005	Expert Rev Anticancer Ther2005，5，1：	1
4	Personalizing CA125 levels for ovarian cancer screening显示文摘	Dorigo O Berek JS	2011	Cancer Prev Res(Phila)2011，4，9：	1
5	Resection of diaphragmatic peritoneum and muscle:role in cytoreductive surgery for ovarian cancer显示文摘	Montz FJ Schlaerth JB Berek JS	1989	Gynecol Oncol1989，35，：	1
6	Monoclcnal antibody therapy of ovarian cancer显示文摘	Nicodemus CF Berek JS	2005	Expert Rev Anticancer Ther2005，5，1：	1
7	Survival of patients following secondary cytoreductive surgery in ovarian cancer显示文摘	Berek JS Hacker NF Lagasse LD	1983	Obstet Gynecol1983，61，：	1
8	Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer显示文摘	Berek JS Taylor PT Gordon A	2004	J Clin Oncol2004，22，17：	1
9	Con-stitutive production of IL-6 by ovarian cancer cell lines and by primary ovarian tumor cultures显示文摘	Watson JM Sensintaffar JL Berek JS	1990	Cancer Res1990，50，21：	1
10	Oregovomab maintenance monoimmunotherapy does not Improve outcomes in advanced ovarian cancer显示文摘	Berek JS Peyton Taylor William McGuire	2009	J Clin Oncol2009，27，3：	1
11	The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids:a me- ta-analysis显示文摘	Pritts EA Vanness DJ Berek JS	2015	Gynecol Surg2015，12，3：	1
12	Biologic and immunologic therapies for ovarian cancer显示文摘	Berek JS Schultes BC Nicodemus CF	2003	J Clin Oncol2003，219，10：	1
13	Advances in the management of epithelial ovarian cancer显示文摘	Memarzadeh S Berek JS	2001	J Report Med2001，46，7：	1
14	Advances in the management of epithelial ovarian cancer 显示文摘	Memarzadeh S Berek JS	2001	J Reprod Med2001，7，：	1
15	Surgery during chemotherapy and at relapse of ovarian cancer显示文摘	Berek JS Trope C Vergote I	1999	Ann Oncol1999，10，1：	1
16	Personalizing CA125 levels for ovarian cancer screening显示文摘	Dorigo O Berek JS		0，，：	1
17	Lymph node-positive stage IIIC ovarian cancer: a separate entity? 显示文摘	BEREK JS	2009	Int J Gynecol Cancer2009，19，2：	1
18	Pelvic exenteration for re- current gynecologic maligrlancy: survival and morbidity analy- sis of the 45-year experience at UCLA 显示文摘	Berek JS Howe C Lagasse LD	2005	Gynecol Oncol2005，99，1：	1
19	CA125velocity at relapse is a highly significant predictor of survival post relapse:results of a5-year follow-up survey to a randomized placebo-controlled study of mainte-nance oregovomab immunotherapy in advanced ovarian cancer显示文摘	Berek JS Taylor PT Nicodemus CF	2008	Journal of Immunotherapy2008，31，2：	1
20	Serum interleukin-6 level s correlated diseasestatus in patients with ovarian cancer显示文摘	Berek JS Chung C Kaldi K	1991	Am J Obstet Gyn ecol1991，164，：	1

返回顶部每页显示：

共8页首页上一页第1页下一页末页 /8 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示